Department of Error (DOI:10.1016/S0140-6736(08)60725-4);Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

The Lancet

Volumn 371, Issue 9625, 2008, Pages 1665-1674

  Leonardi, Craig L ^a   Kimball, Alexa B ^b   Papp, Kim A ^c   Yeilding, Newman ^d   Guzzo, Cynthia ^d   Wang, Yuhua ^d   Li, Shu ^d   Dooley, Lisa T ^d   Gordon, Kenneth B ^e  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d CENTOCOR INC   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 23; MONOCLONAL ANTIBODY; PLACEBO; USTEKINUMAB;

ADULT; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; BODY SURFACE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INJECTION SITE REACTION; LOG RANK TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SCORING SYSTEM; SERUM SICKNESS; TREATMENT RESPONSE;

EID: 43449111187     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60796-5     Document Type: Erratum

References (35)

1. G Krueger J Koo M Lebwohl A Menter RS Stern T Rolstad The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation Patient-Membership Survey Arch Dermatol 137 2001 280 284
2. MP Schon W-H Boehncke Psoriasis N Engl J Med 352 2005 1899 1912
3. BJ Nickoloff SR Stevens What have we learned in dermatology from the biologic therapies? J Am Acad Dermatol 54 3 suppl 2 2006 S143 S151
4. W Sterry J Barker W-H Boehncke Biological therapies in the systemic management of psoriasis Br J Dermatol 151 2004 3 17
5. M Cargill SJ Schrodi M Chang A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes Am J Hum Genet 80 2007 273 290
6. RH Duerr KD Taylor SR Brant A genome-wide association study identifies IL23R as an inflammatory bowel disease gene Science 314 2006 1461 1463
7. F Capon P Di Meglio J Szaub Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis Hum Genet 122 2007 201 206
8. G Piskin RMR Sylva-Steenland JD Bos MBM Teunissen In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin J Immunol 176 2006 1908 1915
9. K Hong A Chu BR Ludviksson EL Berg RO Ehrhardt IL-12, independently of IFN-γ, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder J Immunol 162 1999 7480 7491
10. DC Torti SR Feldman Interleukin-12, interleukin-23, and psoriasis: current prospects J Am Acad Dermatol 57 2007 1059 1068
11. GG Krueger RG Langley C Leonardi A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis N Engl J Med 356 2007 580 592
12. A Kimball KB Gordon RG Langley Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial Arch Dermatol 144 2008 200 207
13. KA Papp RG Langley M Lebwohl Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684
14. S Pocock R Simon Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 31 1975 103 115
15. T Fredriksson U Pettersson Severe psoriasis—oral therapy with a new retinoid Dermatologica 157 1978 238 244
16. AY Finlay GK Khan Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use Clin Exp Dermatol 19 1994 210 216
17. D Geng G Shankar A Schantz M Rajadhyaksha H Davis C Wagner Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies J Pharm Biomed Anal 39 2005 364 375
18. KB Gordon SR Feldman JY Koo A Menter T Rolstad G Krueger Definitions of measures of effect duration for psoriasis treatments Arch Dermatol 141 2005 82 84
19. E Smith A Zarbock MA Stark IL-23 is required for neutrophil homeostasis in normal and neutrophilic mice J Immunol 179 2007 8274 8279
20. G Trinchieri Interleukin-12 and the regulation of innate resistance and adaptive immunity Nat Rev Immunol 3 2003 133 146
21. JG Krueger The immunologic basis for the treatment of psoriasis with new biologic agents J Am Acad Dermatol 46 2002 1 23
22. NJ Wilson K Boniface JR Chan Development, cytokine profile and function of human interleukin 17-producing helper T cells Nat Immunol 8 2007 950 957
23. D Bruch-Gerharz K Fehsel C Suschek G Michel T Ruzicka V Kolb-Bachofen A proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes J Exp Med 184 1996 2007 2012
24. BJ Nickoloff Cracking the cytokine code in psoriasis Nat Med 13 2007 242 244
25. S Vanden Eijnden S Goriely D De Wit F Willems M Goldman IL-23 upregulates IL-10 and induces IL-17 synthesis by polyclonally activated naïve T cells in human Eur J Immunol 35 2005 469 475
26. Y Zheng DM Danilenko P Valdez Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis Nature 445 2007 648 651
27. FO Nestle C Conrad The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis J Invest Dermatol 123 2004 XIV XV
28. CS Carlin SR Feldman JG Krueger A Menter GG Krueger A 50% reduction in the psoriasis area and severity index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis J Am Acad Dermatol 50 2004 859 866
29. JM Gelfand AL Neimann DB Shin X Wang DJ Margolis AB Troxel Risk of myocardial infarction in patients with psoriasis JAMA 296 2006 1735 1741
30. AL Neimann DB Shin X Wang DJ Margolis AB Troxel JM Gelfand Prevalence of cardiovascular risk factors in patients with psoriasis J Am Acad Dermatol 55 2006 829 835
31. C Fieschi JL Casanova The role of interleukin-12 in human infectious diseases: only a faint signature Eur J Immunol 33 2003 1461 1464
32. R de Jong F Altare IA Haagen Severe mycobacterial and salmonella infections in interleukin-12 receptor-deficient patients Science 280 1998 1435 1438
33. S Philipp K Wolk S Kreutzer The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder Expert Opin Ther Targets 10 2006 817 831
34. RS Stern T Nijsten SR Feldman DJ Margolis T Rolstad Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction J Invest Dermatol Symp Proc 9 2004 136 139
35. HL Richards DG Fortune CE Griffiths Adherence to treatment in patients with psoriasis J Eur Acad Dermatol Venereol 20 2006 370 379